araag2/HINT huggingface dataset:
Clinical trial NCT00307684 (phase 3, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: double blind placebo, double blind pr oros methylphenidate, open label pr oros methylphenidate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1, [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has completed study CR002479 (42603ATT3002), according to protocol

          -  Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental
             Diseases, Fourth Edition (DSM-IV)1 and confirmed by the Conners' Adult ADHD Diagnostic
             Interview for DSM IV (CAADID)

          -  Healthy on the basis of physical examination, medical history

          -  Patient is able to comply with the study visit schedule and willing and able to
             complete the protocol-specified assessments

          -  Amendment (double-blind placebo-controlled period): written informed consent

          -  patient must have completed at least 52 weeks of open-label treatment and must have
             been on a stable daily dose of (PR) OROS methlyphenidate prior to inclusion to this
             phase

        Exclusion Criteria:

          -  Patient is known to be a non-responder to methylphenidate, or patient has a child
             known to be a non-responder to methylphenidate

          -  Allergy or hypersensitivty to methlyphenidate

          -  Any clinically unstable psychiatric condition including but not limited to the
             following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder
             (OCD), Anti-social personality disorder, borderline personality disorder

          -  Use of other anti-depressants (unless patient has been on a stable dosage during the
             42603ATT3002 trial, in which case treatment may continue as long as dosage remains
             unchanged for the duration of the study) or mood stabilisers (e.g. anti-epileptics,
             lithium)

          -  Any medication likely to interfere with safe administration of methylphenidate, or any
             conditions that are contraindicated for use of methlyphenidate
Clinical trial NCT00615602 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, trastuzumab, epirubicin, cyclophosphamide, 5-fluoruracil, granulocyte-colony stimulating growth factor, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Women with histologically-confirmed unilateral invasive ductal or lobular breast
             adenocarcinoma

          -  HER2/c-neu over expression should be documented by either immunohistochemistry (score
             3+) or FISH/CISH positivity. A score of 2+ by immunohistochemistry is acceptable only
             if FISH/CISH positive

          -  Within 60 days after the surgical excision of the primary tumor with tumor-free
             operation margins; at least 10 axillary lymph nodes have to be removed.

          -  Tumor involvement of at least one axillary lymph node (N0 with HER2/c-neu over
             expression are also eligible)

          -  Absence of any clinical or radiological evidence of local or metastatic disease

          -  Premenopausal or postmenopausal women aged 18-75 years old

          -  Adequate bone marrow function (absolute neutrophil count >1500/mm3, platelet count
             >100.000/mm3, hemoglobin >10gr/mm3)

          -  Adequate liver (bilirubin <1.0 times upper limit of normal and SGOT/SGPT <2.5 times
             upper limit of normal) and renal function (creatinine <1.5mg/dl)

          -  Adequate cardiac function (LVEF>50%). Normal electrocardiogram and absence of
             significant heart disease

          -  Written informed consent

        Exclusion Criteria:

          -  Positive pregnancy test.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy,
             chemotherapy, biological agents.

          -  Previous history of other invasive malignancy other than non-melanomatous skin cancer.
Clinical trial NCT01396057 (phase 3, status: completed)
Conditions: visual impairment, macular edema, branch retinal vein occlusion
ICD codes: Z73.82, G31.84, M10.38, M10.30, M10.311, M10.312, M10.319, H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120, H34.8332, H34.8331, H34.8311, H34.8321, H34.8391, H34.8312, H34.8322
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with visual impairment due to macular edema following BRVO

          -  Diagnosis of BRVO at maximum 6 months prior to Screening

          -  BCVA using ETDRS charts of 20/40 to 20/400 in the study eye

        Exclusion Criteria:

          -  Media clarity, pupillary dilation and patient cooperation not sufficient for adequate
             fundus photographs

          -  Central retinal thickness (CRT) < 250 µm in the study eye

          -  Prior episode of RVO in the study eye

          -  Active formation of new vessels in the study eye

          -  Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline

          -  IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be re-screened after 1 month if
             they have undergone glaucoma treatment

          -  Improvement of > 10 letters on BCVA between Screening and Baseline

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00507234 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: formoterol fumarate inhalation solution
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Medical diagnosis of COPD

          -  Current or prior history of cigarette smoking

        Exclusion Criteria:

          -  Medical diagnosis of asthma

          -  Significant condition or disease other than COPD
Clinical trial NCT00054418 (phase 3, status: completed)
Conditions: breast cancer, osteoporosis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: risedronate sodium
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        1. Required Characteristics

               1. Premenopausal women

                    -  ≤ 6 months since last menstrual period

                    -  no prior bilateral oophorectomy

                    -  not on estrogen replacement therapy

                    -  if TAH is performed, with at least one intact ovary, or if > 3 months since
                       last menstrual period, then patients must have premenopausal estrogen levels
                       ≤ 1 month of study entry

               2. Scheduled to undergo adjuvant or neoadjuvant chemotherapy for primary breast
                  cancer (stages I-IIIB)

               3. ≥ 18 years of age

               4. ECOG performance status (PS) 0 or 1

          2. Contraindications

               1. Hypercalcemia (calcium level > 1mg/dL above UNL ≤ 6 months

               2. Hypocalcemia (calcium level > 0.5 mg/dL below UNL ≤ 6 months

               3. Inability to stand or sit upright for at least 30 minutes

               4. Known swallowing disorder

               5. Bone mineral density T score of ≤ - 2.0 at the hip or lumbar spine

                    -  a patient with a T score of - 2.1 is ineligible

                    -  a patient with a T score of - 1.9 is eligible

               6. History of vertebral compression fracture

                    -  Exception: traumatic fracture of the coccyx would not exclude a patient from
                       participation

               7. Corticosteroids at doses > 5 mg daily of prednison or equivalent for > 2 weeks in
                  the past 6 months

               8. Previous treatment with bisphosphonates

               9. Diseases affecting bone metabolism (hyperthyroidism, hyperparathyroidism, and
                  hypercortisolism)

              10. History of severe renal impairment or creatinine > 2.0 mg/dL

              11. Malabsorption syndrome

              12. Estrogen replacement therapy

              13. Oral contraceptive use

              14. Prior bilateral oophorectomy

              15. Pregnant women

                    -  Nursing women

                    -  Women of childbearing potential who are unwilling to employ adequate
                       contraception (condoms, diaphragm, injections, intrauterine device [IUD],
                       surgical sterilization, abstinence, etc.)

                    -  This study involves an investigational agent whose genotoxic, mutagenic and
                       teratogenic effects on the developing fetus and newborn are unknown

              16. Dental extraction, root canal, or implants ≤ 3 months prior to registration or
                  planned during study treatment
Clinical trial NCT00384150 (phase 3, status: terminated)
Conditions: lymphoma, non-hodgkin's
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: galiximab in combination with rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    enrollment challenges due to changes in standards of care resulted in premature termination. no
    safety or efficacy events factored into this action.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in combination
             with Rituximab compared with Rituximab in combination with Placebo) and then relapsed
             or progressed with a TTP >=6 months. Relapsed disease is defined as documented disease
             progression using the International Workshop Response Criteria (IWRC).

          -  Bidimensionally measurable disease with at least 1 lesion >=2.0 cm in a single
             dimension.

          -  Acceptable hematologic, hepatic, and renal function.

        Key Exclusion Criteria:

          -  Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this
             retreatment study.

          -  Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders
             within 3 weeks prior to Study Day 1.

          -  Transfusion-dependent subjects.

          -  Presence of central nervous system (CNS) lymphoma.

          -  Histologic transformation.

          -  Presence of pleural or peritoneal effusion with positive cytology for lymphoma.

          -  Another primary malignancy requiring active treatment.

          -  Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active
             uncontrolled bacterial, viral, or fungal infections; or other conditions that would
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

          -  New York Heart Association Class III or IV cardiac disease or myocardial infarction
             within 6 months prior to Study Day 1.
Clinical trial NCT00655486 (phase 3, status: completed)
Conditions: partial epilepsies, partial onset seizures
ICD codes: G40.011, G40.019, G40.001, G40.009
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Eligible subjects who participated in SP925 [NCT00655551] for treatment of
             partial-onset seizures

        Exclusion Criteria:

          -  Receiving any study drug or experimental device other than lacosamide

          -  Meets withdrawal criteria for parent study SP925 [NCT00655551]

          -  Experiencing ongoing serious adverse event
Clinical trial NCT00302822 (phase 3, status: completed)
Conditions: hiv infections, aids
ICD codes: Z21
Drugs: enfuvirtide, emtricitabine/tenofovir, lopinavir or efavirenz
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Antiretroviral naïve HIV-1 infected patients

          -  CD4 cell count below 100 per mm3, or CD4 cell count below 200/mm3 and past history or
             presence of B or C(AIDS defining)event

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy; breast feeding

          -  Coinfection with HIV-2 or infection with HIV-1 subtype O

          -  Antiretroviral pretreated patients

          -  Neoplasia disease currently treated with chemotherapy or radiotherapy

          -  Severe liver failure

          -  Treatment with cytokines or HIV vaccine trial

          -  One or more of the following biological abnormalities: hemoglobin below 10 g/dl,
             Neutrophils below 750 per mm3, thrombocytopenia below 50000 per mm3, creatinine
             clearance below 60 ml per min, Liver Function Tests over 3 Upper Limit of Normal
Clinical trial NCT00189839 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: tacrolimus
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving a kidney transplant from a cadaveric donor or a living non HLA
             identical donor between 5 and 65 years of age with compatible ABO blood type.

          -  Patients with end stage kidney disease who are suitable candidates for primary renal
             transplantation or re-transplantation (unless the graft was lost because of
             immunological reasons within 12 months).

        Exclusion Criteria:

          -  Patients receiving or having previously received an organ transplant other than a
             kidney.

          -  Patients with a high immunological risk, defined as a panel reactive antibodies (PRA)
             grade >50% in the previous 6 months and/or with a previous graft survival of less than
             12 months due to immunological reasons.

          -  Cold ischaemia time of the donor kidney >30 hours.
Clinical trial NCT01071070 (phase 3, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: paricalcitol
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Eligibility criteria:

        Inclusion Criteria:

          1. Subject is a Chinese male or female greater than or equal to 20 years old.

          2. Subject is diagnosed with Chronic Kidney Disease Stage 5 and must be on maintenance
             hemodialysis three times a week for at least 2 months prior to the Screening Visit and
             expected to remain on hemodialysis for the duration of the study.

          3. For entry into the Treatment Phase, the subject must have:

               -  Intact parathyroid hormone greater than or equal to 300 pg/mL

               -  Serum calcium less than 10.2 mg/dL (2.55 mmol/L)

               -  Calcium-phosphorus product less than 65 mg^2/dL^2

        Exclusion Criteria:

          1. Subject has a history of an allergic reaction or significant sensitivity to vitamin D
             or vitamin D related compounds.

          2. Subject received a partial parathyroidectomy within one year prior to the Screening
             Phase.

          3. Subject with New York Heart Association (NYHA) Class III or IV.

          4. Subject has taken aluminum-containing phosphate binders for greater than 3 weeks in
             the last 3 months prior to the Screening Phase, or requires such medications for
             greater than 3 weeks in the study.

          5. Subject has a current malignancy (with the exception of basal or squamous cell
             carcinoma of the skin), or clinically significant liver disease, in the opinion of the
             Investigator.

          6. Subject has a history of drug or alcohol abuse within 6 months prior to the Screening
             Phase.

          7. Subject is known to be human immunodeficiency virus (HIV) positive.

          8. Subject has evidence of poor compliance with diet, medication or hemodialysis that may
             interfere, in the Investigator's opinion, with adherence to the protocol.
Clinical trial NCT00092768 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: mk0663, etoricoxib, comparator: celecoxib
SMILES: CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Osteoarthritis of the knee or hip which requires treatment with a medication to obtain
             pain relief

        Exclusion Criteria:

          -  Any known allergy to the study drugs
Clinical trial NCT00623623 (phase 3, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: enoxaparin, tenecteplase, clopidogrel
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          1. Age equal or greater than 18 years

          2. Onset of symptoms < 3 hours prior to randomisation 3.12-lead ECG indicative of an
             acute STEMI

        4.Informed consent received

        Exclusion criteria:

        Medical history, procedures, medication administration or the presence of factors that
        would in general predispose to bleeding events and/or the inability to evaluate the study
        primary endpoint
Clinical trial NCT00558428 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: fixed dose combination of telmisartan+amlodipine, amlodipine
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. patients aged at least 18 years at the date of signing the consent form

          2. diagnosis of essential hypertension and blood pressure not adequately controlled
             before enrolment in the study

          3. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy

          4. able to stop any current antihypertensive therapy without unacceptable risk to the
             patient (Investigator's decision)

          5. willing and able to provide written informed consent (in accordance with Good Clinical
             Practice and local legislation).

        Exclusion Criteria:

          1. are not practising acceptable means of birth control or do not plan to continue using
             acceptable means of birth control throughout the study and do not agree to submit to
             pregnancy testing during participation in the trial. Acceptable methods of birth
             control include the transdermal patch, oral, implantable or injectable contraceptives,
             sexual abstinence and vasectomised partner.

          2. known or suspected secondary hypertension

          3. mean seated systolic blood pressure (SBP) over 200 mmHg and/or mean seated diastolic
             blood pressure (DBP) over 120 mmHg at Visit 1 or 2 or mean seated SBP over 180 mmHg
             and/or mean seated DBP over 120 mmHg at the end of the run-in period (Visit 3)

          4. any clinically significant hepatic impairment (e.g. clinically significant
             cholestasis, biliary obstructive disorder or hepatic insufficiency)

          5. severe renal impairment (e.g. serum creatinine >3.0 mg/dL or >265 mcmol/L, known
             creatinine clearance <30mL/min or clinical markers of severe renal impairment)

          6. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or
             post-renal transplant

          7. clinically relevant hyperkalaemia

          8. uncorrected volume or sodium depletion.

          9. primary aldosteronism.

         10. hereditary fructose or lactose intolerance
Clinical trial NCT00457899 (phase 3, status: terminated)
Conditions: schizophrenia, schizoaffective disorders, psychotic disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: quetiapine ir (immediate release)
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Reason stopped: 
    study terminated due to poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, aged 18 to 65 years, who require treatment for an acute episode of
             schizophrenia/schizoaffective disorder as judged by their doctor

        Exclusion Criteria:

          -  Significant and unstable conditions of hear, circulation, blood, liver, kidney;
             malignancies (cancer); diabetes (mellitus); history of fits or fainting. Resistance to
             antipsychotic medication. Current alcohol/drug abuse. Pregnant/breast feeding women.
Clinical trial NCT00277914 (phase 3, status: completed)
Conditions: sexual dysfunctions, psychological
ICD codes: O9A.52, F88, F89, O9A.53, T74.31XS, T74.32XS, T76.31XS
Drugs: flibanserin
SMILES: FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Women over 18 and pre-menopausal

          2. FSDS-R above 14

          3. Willingness to try to have sexual activity at least monthly

          4. Willingness to use an electronic diary daily

          5. Stable, monogamous, heterosexual relationship for at least one year

          6. Medically acceptable method of contraception

        Exclusion Criteria:

          1. Clinically relevant conditions which might interfere with the patient's abil ity to
             participate in the trial

          2. Specified medications

          3. Sexual function affected by medication

          4. Drug dependence or abuse

          5. Sexual partner needing treatment

          6. Peri-Menopause or Menopause (surgical or otherwise)

          7. Pregnancy

          8. Pelvic Inflammatory Disease

          9. Major depressive Episode

         10. Significant ECG abnormalities

         11. Significant Neurologic findings

         12. Significant GI, Hepatic, Cardiovascular, Renal, Hematologic, Immunologic or
             Respiratory findings

         13. Uncorrected thyroid or endocrine disease

         14. Uncontrolled Glaucoma